Matrix metalloproteinase inhibitors 1998

Bibliography

• BECKETT RP, DAVIDSON AH, DRUMMOND AH et al: Re- cent advances in matrix metalloproteinase inhibitor research. Drug Disc. Today (1996) 1:16–26.
   Web of Science ®Google Scholar
• MILLER A, ASKEW M, BECKETT RP et al.: Inhibition of ma-trix metalloproteinases: an examination of the Si' pocket. Bioorg. Med. Chem. Lett. (1997) 7:193–198.
   Google Scholar
• BECKETT RP: Recent advances in the field of matrixmetalloproteinase inhibitors. Exp. Opin. Ther. Patent (1996) 6:1305–1315.
   Google Scholar
• ZASK A, LEVIN JI, KILLAR LM et al: Inhibition of matrixmetalloproteinases: structure based design. Curr. Pharm. Design. (1996) 2:624–661.
   Web of Science ®Google Scholar
• HAGMANN WK, LARK MW, BECKER JW et al.: Inhibitionof matrix metalloproteinases. Ann. Rep. Med. Chem. (1996) 31:231–240.
   Google Scholar
• DAVIDSON AH, DRUMMOND AH, GALLOWAY WA, WHITTAKER M: The inhibition of matrix metalloprote-inase enzymes. Chem. Ind. (1997) 258–261.
   Google Scholar
• WHITE AD, BOCAN TMA, BOXER PA et al.: Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr. Pharm. Design (1997) 3:45–58.
   Web of Science ®Google Scholar
• BABINE RE, BENDER SL: Molecular recognition of protein-ligand complexes: applications to drug de-sign. Chem. Rev. (1997) 97:1359–1472.
   PubMed Web of Science ®Google Scholar
• TALBOT DC, BROWN PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibi-tors for the treatment of cancer. Eur. J. Cancer (1996) 32A:2528–2533.
   PubMedGoogle Scholar
• CAWSTON T: metalloproteinase inhibitors and the pre-vention of connective tissue breakdown. Pharmacol Ther. (1996) 70:163–182.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR: The matrix metalloproteinases andtheir inhibitors in pancreatic cancer. Int. J. Pancreatol. (1997) 21:1–12.
   PubMedGoogle Scholar
• DENIS LJ, VERWEIJ J: Matrix metalloproteinase inhibi-tors: present achievements and future prospects. In-vest. New Drugs (1997) 15:175–185.
   PubMed Web of Science ®Google Scholar
• NGO J, GRAUL A, CASTANER J et al.: Batimastat. Drugs of the Future (1996) 21(12):1215–1220.
   Google Scholar
• JACOBSEN IC, REDDY PG, WASSERMAN KD et al: Structure-based design and synthesis of a series of hy-droxamic acids with a quaternary hydroxy group in P1 as inhibitors of matrix metalloproteinases. 213th ACS Meeting, San Francisco CA, 13–17 April 1997. Poster MEDI 079.
   Google Scholar
• EVANS DA, KOZLOWSKI MC, BURGEY CS et al.: C2-sy-mmetric copper (II) complexes as chiral lewis acids. catalytic enantioselective aldol additions of enol-silanes to pyruvate esters. J. Am. Chem. Soc. (1997) 119:7893–7894.
   Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M et al. Processing of tumour necrosis factor alpha by metallo-proteinases. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC, Jr. et al.: Regula-tion of tumour necrosis factor processing by a metallo-proteinase inhibitor. Nature (1994) 370:558–561.
   Google Scholar
• MOHLER KM, SLEATH PR, FITZNER JN et al.: Protectionagainst a lethal dose of endotoxin by an inhibitor of tu-mour necrosis factor processing. Nature (1994) 370:218–220.
   PubMed Web of Science ®Google Scholar
• DIMARTINO M, WOLFF C, HIGH W et al: Anti-arthriticactivity of hydroxamic acid-based pseudopeptide in-hibitors of matrix metalloproteinases and TNF-a proc-essing. Inflamm. Res. (1997) 46:211–215.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, COSSINS JA, WELLS GMA et al.: Matrixmetalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a com-bined matrix metalloproteinase and tumour necrosis factor-a inhibitor. J. Neuroimmunol. (1997) 74:85–94.
   PubMed Web of Science ®Google Scholar
• BLACK R, RAUCH CT, KOZLOSKY CJ et al.: A metallopro-teinase disintegrin that releases tumour necrosis fac-tor-a from cells. Nature (1997) 385:729–732.
   PubMed Web of Science ®Google Scholar
• MOSS ML, JIN S-LC, MILLAR ME et al.: Cloning of a disin-tegrin metalloproteinase that processes tumour ne-crosis factor-a. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• BAILEY S, BOLOGNESE B, BUCKLE DR et al: Selective in-hibition of low affinity IgE receptor (CD23) process-ing. Bioorg. Med. Chem. Lett. (1998) 8:29–34.
   PubMedGoogle Scholar
• DAVIES SJ, BECKETT RP, BELLAMY CL et al.: Use of theIreland-Claisen rearrangement in the synthesis of novel matrix metalloproteinase inhibitors. 9th RSC-SCI Medicinal Chemistly Symposium, Cambridge, UK, 7–10 Sep-tember 1997. Poster presentation.
   Google Scholar
• GRAMS F, CRIMMIN MJ, HINES L et al.: Structure determi-nation and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry (1995) 34:14012–14020.
   PubMed Web of Science ®Google Scholar
• DECICCO CP: The design and synthesis of macrocyclicinhibitors of matrix metalloproteinases and tumour necrosis factor production. SRI Random and Rational Conference, Princeton, New Jersey, 15–16 September 1997.
   Google Scholar
• HANESSIAN S, GRIFFIN A, DEVASTHALE PK: Synthesis ofconformationally constrained potential inhibitors of mammalian metalloproteinases. Bioorg. Med. Chem. Lett. (1997) 7:3119–3124.
   Google Scholar
• MARTIN SF, OALMANN CJ, LIRAS S: Cyclopropanes asconformationally restricted peptide isosteres. design and synthesis of novel collagenase inhibitors. Tetrahe-dron (1993) 49:3521–3532.
   Google Scholar
• TAMAKI K, TANZAWA K, KURIHARA S et al.: Synthesisand structure-activity relationships of gelatinase in-hibitors derived from matlystatins. Chem. Pharm. (1995) 43:1883–1893.
   Google Scholar
• BOTTOMLEY KM, BORKAKOTI N, BRADSHAW D etal.: In-hibition of bovine nasal cartilage degradation by selec-tive matrix metalloproteinase inhibitors. Biochem. J. (1997) 323:483–488.
   Google Scholar
• BAILEY S, BOLOGNESE B, BUCKLE DR et al.:Hydroxamate-based inhibitors of low affinity IgE re-ceptor (CD23) processing. Bioorg. Med. Chem. Lett (1998) 8:23–28.
   PubMedGoogle Scholar
• DECICCO CP, SENG JL, KENNEDY KE et al: Amide surro-gates of matrix metalloproteinase inhibitors: urea and sulfonamide mimics. Bioorg. Med. Chem. Lett. (1997) 7:2331–2336]
   Google Scholar
• JONES RL: Steric inhibition of hydrogen-bonding in asecondary amide. Spectrochimic Acta. (1964) 20:1879–1882
   Google Scholar
• CONRADI RA, HILGERS AR, HO NF, BURTON PS: he in - fluence of peptide structure on transport across caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharmaceut. Res. (1992) 9(3)435–439.
   Google Scholar
• HIRAYAMA R, YAMAMOTO M, TSUKIDA T et al.: Synthe-sis and biological evaluation of orally active matrix metalloproteinase inhibitors. Bioorg. Med. Chem. (1997) 5(4)765–778.
   Google Scholar
• BROADHURST MJ, BROWN PA, LAWTON G et al.: Design and synthesis of the cartilage protective agent (CPA, Ro 32-3555). Bioorg. Med. Chem. Lett. (1997) 7:2299–2302.
   Google Scholar
• MARTIN FM, BELLAMY CL: Unpublished Results (1997).
   Google Scholar
• ABREO MA, AGREE CS, MITCHELL L et al.: Truncated suc-cinamide hydroxamates with nanomolar potency against various MMPs. 213th ACS National Meeting, San Francisco, April 13–17 1997. MEDI 080.
   Google Scholar
• CHEN JJ, ZHANG Y, HAMMOND S et al.: Design, synthe-sis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyc-lic P2'-P3' amide bond isostere. Bioorg. Med. Chem. Lett. (1996) 6:1601–1606.
   Web of Science ®Google Scholar
• JOHNSON WH, ROBERTS NA, BORKAKOTI N: Collage-nase inhibitors: their design and therapeutic use. J. En-zyme Inhib. (1987) 2:1–22.
   PubMedGoogle Scholar
• SCHWARTZ MA, VAN WART HE: Synthetic inhibitors of bacterial and mammalian interstitial collagenases. Prog. Med. Chem. (1992) 29:271–334
   PubMedGoogle Scholar
• BORKAKOTI N, WINKLER FK, WILLIAMS DH et al.: Struc-ture of the catalytic domain of human fibroblast colla-genase complexed with an inhibitor. Nature Struct. Biol. (1994) 1:106–110.
   PubMedGoogle Scholar
• LEWIS EJ, BISHOP J, BOTTOMLEY KMK et al.: Ro 32-3555,an orally active collagenase inhibitor, prevents carti-lage breakdown in vitro and in vivo. Br. J. Pharmacol (1997) 121:540–546.
   PubMed Web of Science ®Google Scholar
• ROBINSON RP, RAGAN JA, CRONIN BJ et al.: Inhibitors ofMMP-1: an examination of P1' Ca gem-disubstitution in the succinamide hydroxamate series. Bioorg. Med. Chem. Lett. (1996) 6:1719–1724.
   Google Scholar
• ROCKWELL A, MELDEN M, COPELAND RA et al.: Comple-mentarity of combinatorial chemistry and structure-based ligand design: application to the discovery of novel inhibitors of matrix metalloproteinases. J. Am. Chem. Soc. (1996) 118:10337–10338.
   Google Scholar
• MACPHERSON LJ, BAYBURT, EK, CAPPARELLI MP et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (1998) 8(3) cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525–2532.
   Google Scholar
• GONNELLA NC, LI Y-C, ZHANG X, PARIS CG: Bioactive conformation of a potent stromelysin inhibitor deter-mined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg. Med. Chem. (1997) 5:2193–2201.
   PubMedGoogle Scholar
• BENDER SL: Structure-based design of MMP inhibitors: discovery and development of AG-3340. 214th ACS Meeting, Las Vegas, 7–11 September 1997. MEDI 108.
   Google Scholar
• SANTOS 0, MCDERMOTT CD, DANIELS RG et al.: Rodent pharmacokinetic and anti-tumour efficacy studies with a series of synthetic inhibitors of matrix metallo-proteinases. Gin. Exp. Metastasis (1997) 15:499–508.
   Google Scholar
• Scrip (1996) 2141:7.
   Google Scholar
• Scrip (1997) 2291:16.
   Google Scholar
• SHUKER SB, HAJDUK PJ, MEADOWS RP et al: Discover-ing high affinity ligands for proteins: SAR by NMR. Sci-ence (1996) 274:1531–1534.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, SHEPPARD G, NETTESHEIM DG etal.: Discov-ery of potent nonpeptide inhibitors of stromelysin us-ing SAR by NMR. J. Am. Chem. Soc. (1997) 119:5818–5827.
   Google Scholar
• FLOYD CD, LEWIS CN, PATEL SR, WHITTAKER M: A method for the synthesis of hydroxamic acids on solid phase. Tetrahedron Lett. (1996) 37:8045–8048.
   Web of Science ®Google Scholar
• RICHTER LS, DESAI MC: A TFA-cleavable linkage for solid-phase synthesis of hydroxamic acids. Tetrahe-dron Lett. (1997) 38:321–322.
   Web of Science ®Google Scholar
• CHEN JJ, SPATOLA AF: Solid phase synthesis of peptide hydroxamic acids. Tetrahedron Lett. (1997) 38:1511–1514.
   Google Scholar
• GORDEEV MF, HUI HC, GORDON EM, PATEL DV: A gen-eral and efficient solid phase synthesis of quinazoline-2,4-diones. Tetrahedron Lett. (1997) 38:1729–1732.
   Web of Science ®Google Scholar
• MELLOR SL MCGUIRE C, CHAN WC: N-Fmoc-aminooxy-2-chlorotrityl polystyrene resin: a facile solid-phase methodology for the synthesis of hydroxamic acids. Tetrahedron Lett. (1997) 38:3311–3314.
   Google Scholar
• BAUER U, HO W-B, KOSKINEN AMP: A novel linkage for the solid-phase synthesis of hydroxamic acids. Tetra-hedron Lett. (1997) 38:7233–7236.
   Google Scholar
• NGU K, PATEL DV: A new and efficient solid phase syn-thesis of hydroxamic acids. J. Org. Chem. (1997) 62:7088–7089.
   PubMedGoogle Scholar
• IMS R&D Focus.
   Google Scholar
• ESSER CK, KEVIN NJ, YATES NA et al: Solid phase synthe-sis of a /V-carboxyalkyl tripeptide combinatorial li-brary. Bioorg. Med. Chem. Lett. (1997) 7:2639–2644.
   Google Scholar
• ESSER CK, BUGIANESI RL, CALDWELL CG et al.: Inhibi-tion of stromelysin-1 (MMP-3) by Pr-biphenylylethyl carboxyalkyl dipeptides. J. Med. Chem. (1997) 40:1026–1040.
   PubMed Web of Science ®Google Scholar
• CHERNEY RJ, DECICCO CP, NELSON DJ et al: Potent car-boxylate inhibitors of stromelysin containing P2' piperazic acids and P1' biaryl moieties. Bioorg. Med. Chem. Lett. (1997) 7:1757–1762.
   Google Scholar
• WANG Q, PFEIFFER, B, TUCKER GC et al.: Asymmetricsynthesis of a conformationally constrained N-phoshonoalkyl dipeptide. Bioorg. Med. Chem. Lett. (1997) 7:2477–2480.
   Google Scholar
• BAXTER AD, BIRD J, BHOGAL R et al.: A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorg. Med. Chem. Lett. (1997) 7:897–902.
   Web of Science ®Google Scholar
• BAXTER AD, BHOGAL R, BIRD JB et al: Mercaptoacyl ma-trix metalloproteinase inhibitors: the effect of substi-tution at the mercaptoacyl moiety. Bioorg. Med. Chem. Lett. (1997) 7:2765–2770.
   Google Scholar
• Exp. Opin. Ther. Patents (1997) 7:1213–1216.
   Google Scholar
• Chiroscience Group plc, Interim Results, 1 October, 1997.
   Google Scholar
• Business Wire, 5 January, 1998.
   Google Scholar
• CAMPBELL DA, BERMAK JC, BURKOTH TS et al: A transi-tion state analogue inhibitor combinatorial library. J. Am. Chem. Soc. (1995) 117:5381–5382.
   Web of Science ®Google Scholar
• SCHULLEK JR, BUTLER JH, NI Z-J et al.: A high density screening format for encoded combinatorial libraries: assay miniaturisation and its application to enzymatic reactions. Anal. Biochem. (1997) 246:20–29.
   PubMedGoogle Scholar
• FOLEY MA, HASSMAN AS, DREWRY DH et al.: Rapid syn-thesis of novel dipeptide inhibitors of human collage-nase and gelatinase using solid phase chemistry. Bioorg. Med. Chem. Lett. (1996) 6:1905–1910.
   Web of Science ®Google Scholar
• CALCAGNI A, ROSSI D, D'ALESSIO S et al.: Inhibitors of Zn-dependent metallopeptidases: synthesis and activ-ity of N-(2-Furoy1)-(Z)-a,13-didehydroleucyl-L-trypt-ophan. ilFarmaco (1993) 48:1271–1277.
   Google Scholar
• FERRY G, BOUTIN JA, ATASSI G et al.: Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Mol. Diver. (1996) 2:135–146.
   Google Scholar
• KITADE Y, HAYASHI, M, YATOME C et al.: Inhibitory ef-fect on HT-1080 tumour cell invasion in vitro using 9- (2'-hydroxyethyDadenine 2'-phosphates. Bioorg. Med. Chem. Lett. (1997) 7:833–836.
   Google Scholar
• KEIKO S, SHIMADA K, NOZOE S et al.: Isolation of nicoti-anamine as a gelatinase inhibitor. J. Antibiotics (1996) 49:1284–1285.
   PubMedGoogle Scholar
• LEE H-J, CHUNG M-C, LEE C-H et al.: Gelastatins A and B, new inhibitors of gelatinase A from Westerdykella multispora F50733. J. Antibiotics (1997) 50:357–359.
   PubMedGoogle Scholar
• SUN HH, KAPLITA PV, HOUCK DR et al.: A metalloprote-inase inhibitor from Doliocarpus verruculosus. Phy-tother. Res. (1996) 10:194–197.
   Google Scholar
• PARELLADA J, GUINEA M: Evaluation of plant products as potential inhibitors of collagenase breakdown. Phy-tother. Res. (1996) 10:S59–S61.
   Google Scholar
• DIGIULIO A, BARRACCHINI A, CELLAI L et al. Rifamycins as inhibitors of collagenase activity: their possible © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (1998) 8(3) pharmacological role in collagen degradative dis-eases. Intern. J. Pharmaceutics. (1996) 144:27–35.
   Google Scholar
• GORE M, A'HERN R, STANKIEWICZ M et al: Tumour marker levels during marimastat therapy. Lancet (1996) 348:263.
   PubMed Web of Science ®Google Scholar
• Scrip (1997) 2295:17.
   Google Scholar
• LOLLINI L, HALLER J, EUGUI EM et al: Disease moddifica-don by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis OW American College of Rheumatology 61st National Scientific Meeting, New Or-leans, USA. November 8–12, 1997. Poster No. 341.
   Google Scholar